PDZK1IP1 and carcinoma: According to a study by Guijarro et al. [16] on carcinoma tumor samples from different localizations, MAP17 overexpression is >70% in the ovary, colon, stomach, cervix and thyroid gland and approximately 50% in the lung, uterus and rectum.